hyrotoxic periodic paralysis (TPP) is a rare complication of hyperthyroidism characterized by episodes of muscle weakness and hypokalemia. TPP is often not recognized at first attack due to a very low prevalence among the Caucasian population and usually mild symptoms of hyperthyroidism. We report a case of TPP due to
Graves' disease in a Caucasian male, who presented with 4 paralytic episodes before the diagnosis was made.
Case Report
A 37-year-old Caucasian man was admitted at the hospital for evaluation of episodic muscular weakness. He recalled four similar episodes in the previous 4 months, which started during sleep or post-exercise rest. Attacks consisted of flaccid muscle weakness that varied from mild proximal leg weakness to quadriparesis, involving mainly the lower-limbs. thyrotoxicosis. Treatment with propranolol and methimazole was initiated (see table) . After 1 year of follow-up the patient remains euthyroid and symptom free.
Discussion
The present case describes a Caucasian patient suffering from TPP due to Graves' disease.
TPP is an uncommon and potentially life-threatening complication of thyrotoxicosis characterized by acute and reversible episodes of muscle weakness and hypokalemia. It occurs in about 0.1% to 0.2% of the hyperthyroid population in North America and it is 10 times more frequent in the Oriental population and in males. 1 The age of onset is usually in the third decade of life. 2 The high incidence of this disorder in Asians and the association with the presence of HLA-DRw8 suggests that the basic defect may be genetically determined, but the precise pathogenesis of TPP remains unclear. 3 Although the association with HLA system may suggest an immunogenetic etiology of the TPP, some patients have thyrotoxicosis without an autoimmune mechanism, such as Jod-Basedow phenomenon, thyroiditis, thyroid stimulating hormone-secreting pituitary tumor, abuse of thyroid hormone, solitary toxic thyroid adenoma, and amiodarone-induced thyrotoxicosis. 4 Although episodes of paralysis are not correlated with the severity of the thyrotoxic state, it is known that resolution of TPP occurs once euthyroidism is restored; 1-3 therefore, the presence of excessive thyroid hormones in serum seems necessary for this disorder. It has been shown that patients with TPP have a significantly higher Na-K-ATPase pump number and activity than healthy subjects or thyrotoxic patients without a history of paralysis. 3 Thyroid hormone, β-adrenergic catecholamine, and insulin can increase the pump activity in skeletal muscles, liver, or kidneys. 5 This leads to a shift of potassium into the cells, manifested as low serum potassium, as seen in our patient, but without changing the total body potassium level. This may explain why weakness resolves when potassium returns to the extracellular space.
Hypophosphatemia and hypomagnesemia have also been reported and may contribute to the muscle weakness. 6 Finally, the attacks of paralysis tend to occur during the night, as in our patient, and after stress, alcohol intake, or a carbohydrate-rich meal, suggesting a possible role of hyperinsulinemia. 3, 7 It has also been described that therapy with glucocorticoid at high-dose, 8 antiretroviral for AIDS, 9 or interferon-alpha are possible precipitating factors.
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A myopathic pattern during attacks of paralysis that disappeared during remission has been reported in electromyogram, while peripheral nerve function remains normal. There are also some case-reports which describe rhabdomyolysis associated with a severe attack of TPP.
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Vacuolation and mitochondrial abnormalities are the most common electron microscopic changes in skeletal muscles. QT-U interval attributable to hypokalemia, and a paradoxically prolonged PR interval due to the thyrotoxicosis. 12 The differential diagnosis for TPP includes familial hypokalemic periodic paralysis (FHPP).
Both disorders are identical in their clinical presentation, but TPP is rarely associated with a positive family history and has a later onset of presentation than FHPP. 7, 13 The recurrent attacks with normal plasma potassium levels between attacks distinguish periodic paralysis from other causes of hypokalemic paralysis. Moreover, mutations in the ionic channel genes such as CACNA1S, SCN4A and KCNE3 have been reported in the FHPP. 5 Definitive treatment of TPP consists in the management of thyrotoxicosis by medical therapy, surgery, or radioactive iodine therapy. Treatment of acute attack is potassium administration, but excessive doses of potassium can lead to hyperkalemia once potassium shifts to extracellular space. 6 No correlation between potassium dose administered and recovery time was observed. To prevent attacks until euthyroid state is achieved, a useful therapy is the administration of a β-adrenergic blocker like propranolol. Other preventive measures that may be effective include a low-carbohydrate diet and potassium-sparing diuretics. 13 Use of potassium supplements is not useful for prophylaxis against further paralytic attacks and it should not be given to patients between episodes.
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Conclusion
In summary, episodes of periodic paralysis usually precede the diagnosis of thyroid dysfunction and does not recur once euthyroidism is achieved. Therefore, it is necessary that Barahona et al. 
